Drug Trial Radar · NCT04809818
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Mar 21, 2021
Primary completion
Aug 5, 2021
Study completion Aug 5, 2021
Sponsor
- Lead sponsor
- Lumosa Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.
Conditions
- Acute Ischemic Stroke
Interventions
LT3001 drug productDrug
Multiple doses of LT3001 drug product administered by intravenous infusion
PlaceboDrug
Multiple doses of Placebo administered by intravenous infusion
AspirinDrug
Loading and maintenance doses of Aspirin administered by oral
ClopidogrelDrug
Loading and maintenance doses of Clopidogrel administered by oral
ApixabanDrug
Multiple doses of Apixaban administered by oral
DabigatranDrug
Multiple doses of Dabigatran administered by oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse EventsTime frame: Adverse events were assessed from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lumosa Phase 1 Unit
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.